China National Accord Medicines Corporation Ltd. (000028.SZ)
ValueMarkers Composite Index
59% below intrinsic value ($9)
China National Accord Medicines Corporation Ltd. (000028.SZ) — VMCI valuation read
Headline read on 000028.SZ: VMCI of 60/100 versus a Healthcare sector median of 50. The 10-point above-median position is what makes China National Accord Medicines Corporation Ltd. a relative-value candidate in the mid-cap cohort, before any pillar-level review.
Form 4 filings on 000028.SZ: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.
**Investor frame.** Three reads on 000028.SZ: value (000028.SZ trades at 19.0x earnings, 6% above the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -2.0x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.
000028.SZ fell 3.0% over the trailing 7 days, with a -14.1% read on a 30-day basis.
China National Accord Medicines Corporation Ltd. engages in the distribution of medicine and pharmaceutical products. The company sells Chinese traditional, bio-chemical, biological, and diagnosis medicines, as well as antibiotics; chemical preparations; food products; chemical products; and various commodities. It also engages in the sale of medical apparatus and instruments; provision of freight transportation, storage, loading and unloading, and professional consultation services; provision of glass wares, cosmetics, and daily merchandise, as well as goods agency services; import and export of technology; leasing of house properties; and wholesale and retail of health products. As of December 31, 2021, the company operated a network of 8,798 drugstores, including 7,257 directly owned stores and 1,541 franchised stores covering 20 provinces, autonomous regions, and municipalities in China. The company was founded in 2004 and is based in Shenzhen, China. China National Accord Medicines Corporation Ltd. is a subsidiary of Sinopharm Group Co., Ltd.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.
Browse More
Key metrics explained
Definitions, formulas, and how ValueMarkers calculates each indicator used in 000028.SZ’s VM Score.
Explore More
Popular Stocks
- Apple (AAPL)Apple value analysis · VMCI score, DCF, MOS
- Microsoft (MSFT)Microsoft value analysis · 120 fundamental indicators
- Alphabet (GOOGL)Alphabet/Google value analysis
- Amazon (AMZN)Amazon intrinsic value and growth profile
- NVIDIA (NVDA)NVIDIA quality, growth, and risk analysis
- Meta Platforms (META)Meta value analysis · VMCI breakdown
- Berkshire Hathaway (BRK.B)Berkshire quality + integrity breakdown
- Johnson & Johnson (JNJ)JNJ dividend quality analysis
- Visa (V)Visa moat, growth, and valuation
- JPMorgan Chase (JPM)JPM financials quality analysis
- Coca-Cola (KO)KO dividend king analysis
- Procter & Gamble (PG)PG dividend king fundamentals
Browse ETFs
- All ETFsTop 100 ETFs by AUM with VMCI-Composite scores
- SPY · S&P 500Broad-market ETF holdings analysis
- VOO · Vanguard S&P 500Low-cost S&P 500 exposure
- QQQ · Nasdaq 100Large-cap growth ETF analysis
- VTI · Total US MarketTotal US equity market ETF
- SCHD · Dividend ETFDividend-focused ETF holdings breakdown
- VYM · High Dividend YieldHigh-yield US dividend ETF
- DGRO · Dividend GrowthDividend growth ETF analysis
- XLK · Tech SectorTechnology sector ETF holdings
- VNQ · Real EstateUS REIT-focused ETF analysis
- GLD · GoldPhysical-gold-backed ETF
- ARKK · Disruptive InnovationThematic growth ETF holdings
Dividend Stocks
- All Dividend Stocks500+ dividend payers with safety scoring
- Dividend Kings50+ years of consecutive dividend growth
- Dividend Aristocrats25+ years of growth · S&P 500 members
- Dividend Contenders10-24 years of dividend growth
- Dividend Challengers5-9 years of dividend growth
- Safe-Yield DividendsQuality > 70 · low-risk dividend payers
- High-Yield DividendsStocks yielding 5%+ with payout health checks
- Dividend Growth10%+ five-year dividend CAGR
- Foreign DividendsNon-US dividend ADRs with VMCI scores
- Coca-Cola (KO) DividendKO dividend deep dive · DRIP projection
- JNJ Dividend AnalysisJohnson & Johnson dividend safety profile
- Procter & Gamble (PG) DividendPG dividend king status
Financial Glossary
- All Definitions120+ value-investing indicators explained
- Piotroski F-ScoreFinancial-strength signal 0-9
- Altman Z-ScoreBankruptcy-distress indicator
- Beneish M-ScoreEarnings-manipulation detection
- Margin of SafetyGraham's discount to intrinsic value
- DCF Intrinsic ValueDiscounted cash-flow valuation
- Graham NumberDefensive-investor fair-value formula
- P/E Ratio (TTM)Trailing price-to-earnings multiple
- EV/EBITDAEnterprise-value to EBITDA multiple
- FCF YieldFree-cash-flow per share / price
- ROICReturn on invested capital · quality signal
- ROIC-WACC SpreadEconomic profit signal
- WACCWeighted average cost of capital
- Dividend YieldAnnual dividend per share / price
- Owner EarningsBuffett's preferred cash-flow metric
Compare Competitors
- All ComparisonsCompare 67+ stock analysis tools
- vs GuruFocusDetailed feature and pricing comparison
- vs TIKRSide-by-side platform comparison
- vs MorningstarCompare analysis capabilities
- vs FinvizScreener comparison and review
- vs Seeking AlphaResearch platform comparison
- vs Simply Wall StVisual analysis comparison
- vs Yahoo FinanceFree tool comparison
- vs ZacksEarnings rank vs fundamental analysis
- vs StockopediaStockRanks vs DCF comparison
- vs Stock RoverPortfolio analytics comparison
- vs KoyfinTerminal-style tool comparison
- vs TradingViewCharting platform comparison
- vs Alpha SpreadValuation tool comparison
- vs WisesheetsExcel/Sheets add-in comparison
- vs MacroaxisData portal vs analysis platform
- vs Old School ValueGraham-style analysis comparison
- vs TIKR TerminalData terminal vs screener comparison